REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Resources for patients and caregivers

Share these helpful tools and resources with patients with MDS and their caregivers.

Full Prescribing Information

Explore the full Prescribing Information, including Boxed WARNINGS.

Medication Guide

Read the Medication Guide and help patients understand the potential side effects associated with REVLIMID treatment.


Additional patient resources.

This list of independent organizations is provided as an additional resource for obtaining information on MDS. Inclusion on this list does not indicate endorsement by Celgene Corporation, a Bristol Myers Squibb company, of an organization or its communications.

Association of Cancer Online Resources 212-226-5525

CancerCare® 800-813-4673

Family Caregiver Alliance® 800-445-8106

National Alliance for Caregiving (online only)

National Coalition for Cancer Survivorship 301-650-9127

Caregiver Action Network 202-772-5050

Well Spouse® Association

MDS Foundation 1-800-MDS-0839

The Aplastic Anemia and MDS International Foundation (AAMDSIF) 800-747-2820 or 301-279-7202

Learn more about the Lenalidomide REMS program.

Find Out Now